GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2020 and provided a business update.
Read more here:
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update
CANTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three and nine months ended September 30, 2020.
Read more:
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three and nine months ended September 30, 2020 and provided an update on key initiatives.
Visit link:
Tricida Announces Third Quarter 2020 Financial Results
Expansion in international and seed treatment markets led revenue growth and gross margin improvement Expansion in international and seed treatment markets led revenue growth and gross margin improvement
More here:
Marrone Bio Innovations, Inc. Reports Third-Quarter 2020 Financial Results
Reported 84 thousand tests in the third quarter, up 12% compared to the second quarter
Read this article:
Progenity Provides Corporate Updates and Reports Third Quarter 2020 Financial Results
Sydney, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release
See the rest here:
Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC
NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company developments.
Read more:
TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
CHATHAM, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will be an invited speaker at the 3rd Annual Neuropsychiatric Drug Development Summit being held virtually November 10-12, 2020.
See more here:
Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit
Product revenue for the first nine months of 2020 increased 29% year-over-year to $30.8 million
More:
Fortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights